title: In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.
abstract: In over a decade (2002 to 2012) of Staphylococcus aureus surveillance testing on 62,195 isolates, dalbavancin was demonstrated to be active against isolates that were either susceptible or nonsusceptible to daptomycin, linezolid, or tigecycline. Nearly all (99.8%) multidrug-resistant methicillin-resistant S. aureus isolates were inhibited by dalbavancin at ≤0.12 μg/ml (MIC50/90, 0.06/0.06 μg/ml), the current U.S. Food and Drug Administration (U.S. FDA) breakpoint. Overall, only 0.35% of the monitored S. aureus isolates had a dalbavancin MIC of either 0.25 or 0.5 μg/ml (i.e., were nonsusceptible).
authors.affiliation: Durata Therapeutics, Branford, Connecticut, USA mccurdysp@comcast.net.
authors.forename: Sandra P
authors.initials: SP
authors.lastname: McCurdy
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
authors.affiliation: JMI Laboratories, North Liberty, Iowa, USA.
authors.forename: Rodrigo E
authors.initials: RE
authors.lastname: Mendes
authors.affiliation: Durata Therapeutics, Branford, Connecticut, USA.
authors.forename: Sailaja
authors.initials: S
authors.lastname: Puttagunta
authors.affiliation: Durata Therapeutics, Branford, Connecticut, USA.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Dunne
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D062665:Epidemiological Monitoring; D006801:Humans; D000069349:Linezolid / Q000494:pharmacology; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000494:pharmacology; D000078304:Tigecycline; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D000078304:Tigecycline; C469289:dalbavancin; D008911:Minocycline; D000069349:Linezolid; D017576:Daptomycin